Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Jena – page 16

349 clinical trials in Jena, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Jena at a glance
349
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

349 trials in Jena

Open in trial search

Bronchiectasis

Not yet recruiting

Study of Nebulized Human Normal Immunoglobulin (CSL787) for Adults with Non-cystic Fibrosis Bronchiectasis to Find Best Dose and Test Safety

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:CSL Behring LLC

Amyotrophic lateral sclerosis

Not yet recruiting

Study on the Effectiveness and Safety of Masitinib and Riluzole for Patients with Amyotrophic Lateral Sclerosis (ALS)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Masitinib
  • Sponsor:Ab Science

Diffuse large B-cell lymphoma+2

Not yet recruiting

Study of Loncastuximab Tesirine and Epcoritamab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, or Follicular Lymphoma Grade 3B

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:Universitaet Muenster

Gastrooesophageal cancer+1

Not yet recruiting

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan with Drug Combination for Patients with HER2+ Resectable Esophagogastric Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Immune-mediated myositis

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel and Drug Combination for Patients with Severe Refractory Inflammatory Muscle Diseases

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Systemic lupus erythematosus+1

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Novartis Pharma AG

Nervous system disorder+1

Not yet recruiting

Study of KYV-101 Therapy for Patients with Refractory Primary and Secondary Progressive Multiple Sclerosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:KYV-101
  • Sponsor:Kyverna Therapeutics Inc.

Systemic scleroderma

Not yet recruiting

Study comparing rapcabtagene autoleucel and rituximab in patients with severe refractory diffuse cutaneous systemic sclerosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Magnetic resonance imaging

Not yet recruiting

Study on How Gadoquatrane Works and Its Safety in Children Undergoing MRI Scans

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Gadoquatrane
  • Sponsor:Bayer AG

Acute myeloid leukaemia

Not yet recruiting

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:GPOH gGmbH

Acute myeloid leukaemia+1

Not yet recruiting

Study on the Effectiveness and Safety of Imetelstat for Patients with High-Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia After HMA Therapy Failure

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Hydrocortisone
  • Sponsor:Gcp-Service International West GmbH

Hepatitis alcoholic+1

Not yet recruiting

Study on the Safety and Effects of Resatorvid and Filgrastim for Patients with Severe Alcoholic Hepatitis and Acute-on-Chronic Liver Failure

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Filgrastim
  • Sponsor:Alpha Bioresearch S.L.

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Jena

What the registry says about research in the country

01 Oncology Research

Advanced clinical trials focusing on multiple myeloma, prostate cancer, and gastric cancer treatments. Studies evaluating novel therapeutic combinations and targeted approaches for various cancer types.

  • Hematologic Malignancies
  • Solid Tumors
  • Targeted Therapies

Innovative treatments including antibody-drug conjugates and immunotherapy combinations for improved patient outcomes.

02 Cardiovascular Studies

Research investigating treatments for hypertrophic cardiomyopathy and advanced cardiovascular disease. Trials exploring new approaches to reduce major cardiovascular events and improve patient quality of life.

  • Heart Disease Management
  • Cardiovascular Risk Reduction
  • Novel Therapeutic Approaches

Focus on both preventive measures and treatment of established cardiovascular conditions.

03 Autoimmune Disorders

Clinical investigations of treatments for systemic lupus erythematosus, Sjögren's Disease, and other autoimmune conditions. Studies evaluating new biological therapies and targeted treatments.

  • Inflammatory Diseases
  • Immunotherapy
  • Disease-Modifying Treatments

Comprehensive research into improving treatment outcomes for patients with chronic autoimmune conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.